Matritech has entered a strategic R&D collaboration with SBMC to accelerate the development of a next-generation regenerative biomaterial-based therapies. The collaboration, representing a total project value of €850,000, is supported by an SBMC research grant, with co-funding provided by Matritech and its partners.
This grant mechanism is designed to support ambitious biomaterials innovation and is also open to other SBMC clients seeking to de-risk and accelerate early-stage R&D through access to SBMC’s facilities, expertise and quality infrastructure.
Leveraging the body’s regenerative capacity
Matritech is a biotech company developing minimally invasive regenerative therapies with a focus on durable tissue repair. Its work centers on restoring key elements of the local biological environment to support functional recovery. By translating advances in regenerative science into clinically relevant solutions, Matritech aims to develop patient-focused therapies that address clear unmet medical needs.
SBMC as an enabling partner
SBMC supports the collaboration by providing access to its biomaterials expertise, ISO-certified laboratory infrastructure and a professional research environment. As an independent organisation, SBMC facilitates structured collaboration between companies and knowledge partners, with a strong focus on research quality and operational standards.
Through its facilities, governance framework and grant program, SBMC helps reduce barriers for early-stage biomaterials research and supports companies in conducting high-quality R&D within a structured and professionally managed setting. The SBMC grant program is designed to enable such collaborations and remains available to other companies seeking to advance biomaterials innovation.
